Introduction: Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma worldwide. This disease is especially important in Latin America due to the high prevalence in the region (1) (2). In patients with high risk, treatment results have been disappointing. Objective: Evaluate of progression-free survival in patients with high-risk DLBCL by IPI (International Prognostic Index) treated at the Clinica Universitaria Colombia between the years 2012 - 2019 who received EPOCHR or R-CHOP as first line therapy. Materials and methods: A retrospective cohort-type analytical study was conducted. Patients with diagnosis of high-risk DLBCL who received chemotherapy with RCHOP or EPOCH R were selected. Progression-free survival was assessed as the main outcome. The data were evaluated by means of Kaplan Meier curves and compared by means of log Rank test, a multivariate analysis was carried out through a Cox model. Results: The median progression-free survival in the RCHOP group was 61.7 months (95% CI 15.2 - NA), while in the group that received the EPOCH R it had not been reached at the time of follow-up. The probability of progression-free survival at 2 years was 66% (95% CI 44.4% to 98.2%) and 63% (95% CI 50.6% to 78.4%) for EPOCHR and RCHOP, respectively (p = 0.7), no differences in overall survival were found- Conclusion: No differences were found in terms of progression-free survival between the two treatments.